Previous Close | 0.4950 |
Open | 0.4750 |
Bid | 0.4702 x 1200 |
Ask | 0.5000 x 1100 |
Day's Range | 0.4537 - 0.5378 |
52 Week Range | 0.4500 - 1.3900 |
Volume | |
Avg. Volume | 71,145 |
Market Cap | 51.689M |
Beta (5Y Monthly) | 0.24 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1800 |
Earnings Date | Apr 23, 2024 - Apr 27, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for TLSA
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studiesNeuroinflammation modulation may be synergistic to approved treatments in Alzheimer’s Disease NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-
By John Vandermosten, CFA NASDAQ:TLSA Tiziana Life Sciences PLC (NASDAQ:TLSA) has achieved a significant milestone dosing its first patient in its Phase IIa study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The company also recently dosed four new patients in its expanded access (EA) multiple sclerosis
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in mi